Treating cancer in its earliest stages is almost always more successful. That’s especially true for certain forms of the disease, such as prostate cancer. Treatment options at EuroMed Foundation for prostate cancer that is detected early include a range of alternative and complementary therapies.
Prostate cancer is difficult to treat, and early detection is the key. According to the National Cancer Institute (NCI), more than 200,000 new prostate cancer cases are reported in American hospitals annually, with about 30,000 patients killed by the disease each year. As many as 1 in 8 men will develop prostate cancer in their lifetime.
But a recent study shows that a new diagnostic test analyzing samples of seminal fluid could reveal early signs of prostate cancer, helping doctors assess the severity of cancer. That’s important because such an early warning tool will help gauge the urgency and type of treatment required. The research findings come as doctors have identified problems with the reliability of prostate-specific antigen (PSA) tests. PSA screening tests are currently the main diagnostic tool physicians use to identify prostate cancer.
Patients diagnosed with prostate cancer benefit from EuroMed Foundation’s alternative cancer treatment, which is focused on eradicating cancer using low-dose chemotherapy and boosting the body’s natural immune system. Pursuing those goals simultaneously sets EuroMed’s holistic approach to treatment for prostate cancer apart from traditional cancer treatment, which patients may find is worse than the disease itself.